Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certolizumab pegol - UCB

Next Previous
Drug Profile

Certolizumab pegol - UCB

Alternative Names: AutoClicks-Prefilled-Pen; CDP-870; Certolizumab; Cimzia; CIMZIA AutoClicks Prefilled Pen; Cimzia AutoClicks Prefilled Pen; CZP; PHA-738144; Simziya

Latest Information Update: 15 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Developer Astellas Pharma; UCB; University of Pennsylvania; University of Southampton; University of Washington
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Fab fragments; Immunotherapies; Nootropics; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Antiphospholipid syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Registered Non-radiographic axial spondyloarthritis
  • Phase III Interstitial cystitis; Juvenile rheumatoid arthritis
  • Phase II Antiphospholipid syndrome; Ulcerative colitis
  • Discontinued Cognition disorders

Most Recent Events

  • 09 Sep 2026 Certolizumab pegol - UCB receives Breakthrough Therapy status for Antiphospholipid syndrome in USA
  • 09 Sep 2026 Certolizumab pegol - UCB receives Orphan Drug status for Antiphospholipid syndrome in USA
  • 23 Jul 2026 UCB Biopharma completes the phase III CIMcare trial in Plaque psoriasis (In children, In adolescent) in USA, Canada, Puerto Rico (SC, Injection) (NCT04123795)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top